Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine to fight breast cancer is currently in the pipeline. It targets the Bcl-2 protein, which appears to contribute to chemotherapy resistance of cancer cells. The medicine aims to reduce the amount of Bcl-2 in cancers, making chemotherapy more effective.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who…  
  • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.  
  • Treating cancer patients with oral medicine versus intravenous chemotherapy results in a 2/3 reduction in hospital time and a greater than 50% reduction in costly medication side effects.  
  • Widespread use of selective estrogen receptor modulators could result in an approximately 30% decrease in breast cancer.  
  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in the pipeline would inhibit production of a protein that may interfere with the effectiveness of chemotherapy.